Editas Medicine Inc Stock

$5.21+0.21 (+4.2%)
Updated Jul 22, 2024
EDIT Price
Fair Value Price
Market Cap
52 Week Low
52 Week High
Dividend Yield
Gross Margin
Operating Margin
Profit Margin
Debt to Equity
Operating Cash Flow
Next Earnings
Jul 31, 2024
Next Dividend

EDIT Overview

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how EDIT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

EDIT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
EDIT is good value based on its book value relative to its share price (1.46x), compared to the US Biotechnology industry average (6.3x)
P/B vs Industry Valuation
EDIT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more EDIT due diligence checks available for Premium users.

Be the first to know about important EDIT news, forecast changes, insider trades & much more!



EDIT fair value

Fair Value of EDIT stock based on Discounted Cash Flow (DCF)
Fair Value
Undervalued by
EDIT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

EDIT price to earnings (PE)

For valuing profitable companies with steady earnings

EDIT price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
EDIT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

EDIT's financial health

Profit margin

Net Income
Profit Margin
EDIT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
EDIT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Debt to equity
EDIT's short-term assets ($305.56M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EDIT's short-term assets ($305.56M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EDIT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
EDIT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

EDIT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

EDIT vs Biotech Stocks

TickerMarket Cap1d %P/EP/B

Editas Medicine Stock FAQ

What is Editas Medicine's quote symbol?

(NASDAQ: EDIT) Editas Medicine trades on the NASDAQ under the ticker symbol EDIT. Editas Medicine stock quotes can also be displayed as NASDAQ: EDIT.

If you're new to stock investing, here's how to buy Editas Medicine stock.

What is the 52 week high and low for Editas Medicine (NASDAQ: EDIT)?

(NASDAQ: EDIT) Editas Medicine's 52-week high was $11.69, and its 52-week low was $4.45. It is currently -55.43% from its 52-week high and 17.08% from its 52-week low.

How much is Editas Medicine stock worth today?

(NASDAQ: EDIT) Editas Medicine currently has 82,237,974 outstanding shares. With Editas Medicine stock trading at $5.21 per share, the total value of Editas Medicine stock (market capitalization) is $428.46M.

Editas Medicine stock was originally listed at a price of $18.20 in Feb 3, 2016. If you had invested in Editas Medicine stock at $18.20, your return over the last 8 years would have been -71.37%, for an annualized return of -14.47% (not including any dividends or dividend reinvestments).

How much is Editas Medicine's stock price per share?

(NASDAQ: EDIT) Editas Medicine stock price per share is $5.21 today (as of Jul 22, 2024).

What is Editas Medicine's Market Cap?

(NASDAQ: EDIT) Editas Medicine's market cap is $428.46M, as of Jul 23, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Editas Medicine's market cap is calculated by multiplying EDIT's current stock price of $5.21 by EDIT's total outstanding shares of 82,237,974.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.